How big is Axogen, Inc.?

As of Jun 18, Axogen, Inc. has a market capitalization of 434.03 million and reported net sales of 194.52 million with a net profit of -7.16 million over the latest four quarters. Shareholder's funds are at 103.91 million, and total assets are 203.73 million as of Dec 24.

As of Jun 18, Axogen, Inc. has a market capitalization of 434.03 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 194.52 million, while the sum of Net Profit for the same period is -7.16 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 103.91 million and Total Assets at 203.73 million.

What does Axogen, Inc. do?

Axogen, Inc. provides surgical solutions for peripheral nerve injuries and operates in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $49 million and a net loss of $4 million, with a market cap of $434.03 million.

Overview: <BR>Axogen, Inc. offers surgical solutions for peripheral nerve injuries and operates within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 49 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 434.03 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.21 <BR>Return on Equity: -7.14% <BR>Price to Book: 4.12<BR><BR>Contact Details: <BR>Address: 13631 Progress Blvd Ste 400, ALACHUA FL: 32615-9409 <BR>Tel: 1 386 4626817 <BR>Fax: 1 386 4626801 <BR>Website: https://www.axogeninc.com/

Should I buy, sell or hold Axogen, Inc.?

Who are in the management team of Axogen, Inc.?

As of March 2022, the management team of Axogen, Inc. includes Ms. Karen Zaderej as Chairman, President, and CEO, with Ms. Amy Wendell as Lead Independent Director and directors Mr. Gregory Freitag, Mr. Paul Thomas, Mr. Quentin Blackford, and Dr. Mark Gold.

As of March 2022, the management team of Axogen, Inc. includes Ms. Karen Zaderej, who serves as the Chairman of the Board, President, and Chief Executive Officer. Other key members of the board include Ms. Amy Wendell as the Lead Independent Director, Mr. Gregory Freitag, Mr. Paul Thomas, Mr. Quentin Blackford, and Dr. Mark Gold, all serving as directors in various capacities.

Is Axogen, Inc. technically bullish or bearish?

As of October 3, 2025, Axogen, Inc. has a bullish trend with strong indicators like a bullish MACD and moving averages, though the weekly RSI shows short-term weakness, and while it has outperformed the S&P 500 recently, it has lagged in the longer term.

As of 3 October 2025, the technical trend for Axogen, Inc. has changed from mildly bullish to bullish. The current stance is bullish, with strength indicated by a bullish MACD on the weekly chart and bullish moving averages on the daily timeframe. However, the weekly RSI is bearish, suggesting some short-term weakness. The Bollinger Bands and KST are both mildly bullish on the weekly, while the Dow Theory shows no trend on the weekly but mildly bullish on the monthly. <BR><BR>In terms of performance, Axogen has outperformed the S&P 500 over the past month with a return of 7.38% compared to the S&P's 4.15%, but it has lagged behind over the longer term, particularly in the 3-year and 5-year periods.